Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.

Wyllie S, Brand S, Thomas M, De Rycker M, Chung CW, Pena I, Bingham RP, Bueren-Calabuig JA, Cantizani J, Cebrian D, Craggs PD, Ferguson L, Goswami P, Hobrath J, Howe J, Jeacock L, Ko EJ, Korczynska J, MacLean L, Manthri S, Martinez MS, Mata-Cantero L, Moniz S, Nühs A, Osuna-Cabello M, Pinto E, Riley J, Robinson S, Rowland P, Simeons FRC, Shishikura Y, Spinks D, Stojanovski L, Thomas J, Thompson S, Viayna Gaza E, Wall RJ, Zuccotto F, Horn D, Ferguson MAJ, Fairlamb AH, Fiandor JM, Martin J, Gray DW, Miles TJ, Gilbert IH, Read KD, Marco M, Wyatt PG.

Proc Natl Acad Sci U S A. 2019 May 7;116(19):9318-9323. doi: 10.1073/pnas.1820175116. Epub 2019 Apr 8.

2.

Nongenotoxic 3-Nitroimidazo[1,2-a]pyridines Are NTR1 Substrates That Display Potent in Vitro Antileishmanial Activity.

Fersing C, Basmaciyan L, Boudot C, Pedron J, Hutter S, Cohen A, Castera-Ducros C, Primas N, Laget M, Casanova M, Bourgeade-Delmas S, Piednoel M, Sournia-Saquet A, Belle Mbou V, Courtioux B, Boutet-Robinet É, Since M, Milne R, Wyllie S, Fairlamb AH, Valentin A, Rathelot P, Verhaeghe P, Vanelle P, Azas N.

ACS Med Chem Lett. 2018 Dec 19;10(1):34-39. doi: 10.1021/acsmedchemlett.8b00347. eCollection 2019 Jan 10.

PMID:
30655943
3.

Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT.

Thwaites GE, Scarborough M, Szubert A, Saramago Goncalves P, Soares M, Bostock J, Nsutebu E, Tilley R, Cunningham R, Greig J, Wyllie SA, Wilson P, Auckland C, Cairns J, Ward D, Lal P, Guleri A, Jenkins N, Sutton J, Wiselka M, Armando GR, Graham C, Chadwick PR, Barlow G, Gordon NC, Young B, Meisner S, McWhinney P, Price DA, Harvey D, Nayar D, Jeyaratnam D, Planche T, Minton J, Hudson F, Hopkins S, Williams J, Török ME, Llewelyn MJ, Edgeworth JD, Walker AS.

Health Technol Assess. 2018 Oct;22(59):1-148. doi: 10.3310/hta22590.

4.

Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani.

Corpas-Lopez V, Moniz S, Thomas M, Wall RJ, Torrie LS, Zander-Dinse D, Tinti M, Brand S, Stojanovski L, Manthri S, Hallyburton I, Zuccotto F, Wyatt PG, De Rycker M, Horn D, Ferguson MAJ, Clos J, Read KD, Fairlamb AH, Gilbert IH, Wyllie S.

ACS Infect Dis. 2019 Jan 11;5(1):111-122. doi: 10.1021/acsinfecdis.8b00226. Epub 2018 Nov 12.

5.

Development of Chemical Proteomics for the Folateome and Analysis of the Kinetoplastid Folateome.

Webster LA, Thomas M, Urbaniak M, Wyllie S, Ong H, Tinti M, Fairlamb AH, Boesche M, Ghidelli-Disse S, Drewes G, Gilbert IH.

ACS Infect Dis. 2018 Oct 12;4(10):1475-1486. doi: 10.1021/acsinfecdis.8b00097. Epub 2018 Sep 28.

6.

Antitrypanosomatid Pharmacomodulation at Position 3 of the 8-Nitroquinolin-2(1H)-one Scaffold Using Palladium-Catalysed Cross-Coupling Reactions.

Pedron J, Boudot C, Bourgeade-Delmas S, Sournia-Saquet A, Paloque L, Rastegari M, Abdoulaye M, El-Kashef H, Bonduelle C, Pratviel G, Wyllie S, Fairlamb AH, Courtioux B, Verhaeghe P, Valentin A.

ChemMedChem. 2018 Oct 22;13(20):2217-2228. doi: 10.1002/cmdc.201800456. Epub 2018 Sep 17.

PMID:
30221468
7.

Author Correction: Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.

Field MC, Horn D, Fairlamb AH, Ferguson MAJ, Gray DW, Read KD, De Rycker M, Torrie LS, Wyatt PG, Wyllie S, Gilbert IH.

Nat Rev Microbiol. 2018 Nov;16(11):714. doi: 10.1038/s41579-018-0085-1.

PMID:
30206344
8.

Clinical and veterinary trypanocidal benzoxaboroles target CPSF3.

Wall RJ, Rico E, Lukac I, Zuccotto F, Elg S, Gilbert IH, Freund Y, Alley MRK, Field MC, Wyllie S, Horn D.

Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):9616-9621. doi: 10.1073/pnas.1807915115. Epub 2018 Sep 5.

9.

8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases.

Fersing C, Boudot C, Pedron J, Hutter S, Primas N, Castera-Ducros C, Bourgeade-Delmas S, Sournia-Saquet A, Moreau A, Cohen A, Stigliani JL, Pratviel G, Crozet MD, Wyllie S, Fairlamb A, Valentin A, Rathelot P, Azas N, Courtioux B, Verhaeghe P, Vanelle P.

Eur J Med Chem. 2018 Sep 5;157:115-126. doi: 10.1016/j.ejmech.2018.07.064. Epub 2018 Aug 1.

PMID:
30092366
10.

Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis.

Wyllie S, Thomas M, Patterson S, Crouch S, De Rycker M, Lowe R, Gresham S, Urbaniak MD, Otto TD, Stojanovski L, Simeons FRC, Manthri S, MacLean LM, Zuccotto F, Homeyer N, Pflaumer H, Boesche M, Sastry L, Connolly P, Albrecht S, Berriman M, Drewes G, Gray DW, Ghidelli-Disse S, Dixon S, Fiandor JM, Wyatt PG, Ferguson MAJ, Fairlamb AH, Miles TJ, Read KD, Gilbert IH.

Nature. 2018 Aug;560(7717):192-197. doi: 10.1038/s41586-018-0356-z. Epub 2018 Jul 25.

11.

Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.

Pedron J, Boudot C, Hutter S, Bourgeade-Delmas S, Stigliani JL, Sournia-Saquet A, Moreau A, Boutet-Robinet E, Paloque L, Mothes E, Laget M, Vendier L, Pratviel G, Wyllie S, Fairlamb A, Azas N, Courtioux B, Valentin A, Verhaeghe P.

Eur J Med Chem. 2018 Jul 15;155:135-152. doi: 10.1016/j.ejmech.2018.06.001. Epub 2018 Jun 5.

PMID:
29885575
12.

Antitrypanosomal 8-Hydroxy-Naphthyridines Are Chelators of Divalent Transition Metals.

Wall RJ, Moniz S, Thomas MG, Norval S, Ko EJ, Marco M, Miles TJ, Gilbert IH, Horn D, Fairlamb AH, Wyllie S.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00235-18. doi: 10.1128/AAC.00235-18. Print 2018 Aug.

13.

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

Thwaites GE, Scarborough M, Szubert A, Nsutebu E, Tilley R, Greig J, Wyllie SA, Wilson P, Auckland C, Cairns J, Ward D, Lal P, Guleri A, Jenkins N, Sutton J, Wiselka M, Armando GR, Graham C, Chadwick PR, Barlow G, Gordon NC, Young B, Meisner S, McWhinney P, Price DA, Harvey D, Nayar D, Jeyaratnam D, Planche T, Minton J, Hudson F, Hopkins S, Williams J, Török ME, Llewelyn MJ, Edgeworth JD, Walker AS; United Kingdom Clinical Infection Research Group (UKCIRG).

Lancet. 2018 Feb 17;391(10121):668-678. doi: 10.1016/S0140-6736(17)32456-X. Epub 2017 Dec 14.

14.

Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani.

Torrie LS, Brand S, Robinson DA, Ko EJ, Stojanovski L, Simeons FRC, Wyllie S, Thomas J, Ellis L, Osuna-Cabello M, Epemolu O, Nühs A, Riley J, MacLean L, Manthri S, Read KD, Gilbert IH, Fairlamb AH, De Rycker M.

ACS Infect Dis. 2017 Oct 13;3(10):718-727. doi: 10.1021/acsinfecdis.7b00047. Epub 2017 Oct 2.

15.

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.

Field MC, Horn D, Fairlamb AH, Ferguson MAJ, Gray DW, Read KD, De Rycker M, Torrie LS, Wyatt PG, Wyllie S, Gilbert IH.

Nat Rev Microbiol. 2017 Jul;15(7):447. doi: 10.1038/nrmicro.2017.69. Epub 2017 Jun 5. No abstract available.

PMID:
28579611
16.

Whole-Genome Sequencing Reveals the Contribution of Long-Term Carriers in Staphylococcus aureus Outbreak Investigation.

Gordon NC, Pichon B, Golubchik T, Wilson DJ, Paul J, Blanc DS, Cole K, Collins J, Cortes N, Cubbon M, Gould FK, Jenks PJ, Llewelyn M, Nash JQ, Orendi JM, Paranthaman K, Price JR, Senn L, Thomas HL, Wyllie S, Crook DW, Peto TEA, Walker AS, Kearns AM.

J Clin Microbiol. 2017 Jul;55(7):2188-2197. doi: 10.1128/JCM.00363-17. Epub 2017 May 3.

17.

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.

Field MC, Horn D, Fairlamb AH, Ferguson MA, Gray DW, Read KD, De Rycker M, Torrie LS, Wyatt PG, Wyllie S, Gilbert IH.

Nat Rev Microbiol. 2017 Feb 27;15(4):217-231. doi: 10.1038/nrmicro.2016.193. [Epub ahead of print] Review. Erratum in: Nat Rev Microbiol. 2017 Jul;15(7):447. Nat Rev Microbiol. 2018 Nov;16(11):714.

18.

Surgical resection of a rare cutaneous manifestation of Scedosporium apiospermum in a patient who underwent renal transplant.

Stoneham AC, Stoneham SE, Wyllie SA, Pandya AN.

BMJ Case Rep. 2017 Jan 23;2017. pii: bcr2016217923. doi: 10.1136/bcr-2016-217923.

19.

Haemagglutinin and neuraminidase sequencing delineate nosocomial influenza outbreaks with accuracy equivalent to whole genome sequencing.

Houghton R, Ellis J, Galiano M, Clark TW, Wyllie S.

J Infect. 2017 Apr;74(4):377-384. doi: 10.1016/j.jinf.2016.12.015. Epub 2017 Jan 16.

PMID:
28104386
20.

Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells.

Koniordou M, Patterson S, Wyllie S, Seifert K.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01228-16. doi: 10.1128/AAC.01228-16. Print 2017 Mar.

21.

Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania.

Wyllie S, Roberts AJ, Norval S, Patterson S, Foth BJ, Berriman M, Read KD, Fairlamb AH.

PLoS Pathog. 2016 Nov 3;12(11):e1005971. doi: 10.1371/journal.ppat.1005971. eCollection 2016 Nov.

22.

Identification of microRNA biomarker candidates in urine and plasma from rats with kidney or liver damage.

Wolenski FS, Shah P, Sano T, Shinozawa T, Bernard H, Gallacher MJ, Wyllie SD, Varrone G, Cicia LA, Carsillo ME, Fisher CD, Ottinger SE, Koenig E, Kirby PJ.

J Appl Toxicol. 2017 Mar;37(3):278-286. doi: 10.1002/jat.3358. Epub 2016 Jul 11.

23.

Epidemiology and clinical presentation of canine distemper disease in dogs and ferrets in Australia, 2006-2014.

Wyllie SE, Kelman M, Ward MP.

Aust Vet J. 2016 Jul;94(7):215-22. doi: 10.1111/avj.12457. Erratum in: Aust Vet J. 2016 Aug;94(8):279.

PMID:
27349880
24.

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis.

Patterson S, Wyllie S, Norval S, Stojanovski L, Simeons FR, Auer JL, Osuna-Cabello M, Read KD, Fairlamb AH.

Elife. 2016 May 24;5. pii: e09744. doi: 10.7554/eLife.09744.

25.

Pentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomes.

Bruhn DF, Wyllie S, Rodríguez-Cortés A, Carrillo AK, Rakesh, Guy RK, Fairlamb AH, Lee RE.

J Antimicrob Chemother. 2016 Apr;71(4):956-63. doi: 10.1093/jac/dkv417. Epub 2015 Dec 18.

26.

Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei.

Wyllie S, Foth BJ, Kelner A, Sokolova AY, Berriman M, Fairlamb AH.

J Antimicrob Chemother. 2016 Mar;71(3):625-34. doi: 10.1093/jac/dkv376. Epub 2015 Nov 17.

27.

Arsenic, antimony, and Leishmania: has arsenic contamination of drinking water in India led to treatment- resistant kala-azar?

Perry M, Wyllie S, Prajapati V, Menten J, Raab A, Feldmann J, Chakraborti D, Sundar S, Boelaert M, Picado A, Fairlamb A.

Lancet. 2015 Feb 26;385 Suppl 1:S80. doi: 10.1016/S0140-6736(15)60395-6.

PMID:
26312902
28.

Prevalence of Hepatitis E Virus Infection in Pigs at the Time of Slaughter, United Kingdom, 2013.

Grierson S, Heaney J, Cheney T, Morgan D, Wyllie S, Powell L, Smith D, Ijaz S, Steinbach F, Choudhury B, Tedder RS.

Emerg Infect Dis. 2015 Aug;21(8):1396-401. doi: 10.3201/eid2108.141995.

29.

The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis.

Wolenski FS, Fisher CD, Sano T, Wyllie SD, Cicia LA, Gallacher MJ, Baker RA, Kirby PJ, Senn JJ.

Cell Death Discov. 2015 Oct 5;1:15034. doi: 10.1038/cddiscovery.2015.34. eCollection 2015.

30.

Homoserine and quorum-sensing acyl homoserine lactones as alternative sources of threonine: a potential role for homoserine kinase in insect-stage Trypanosoma brucei.

Ong HB, Lee WS, Patterson S, Wyllie S, Fairlamb AH.

Mol Microbiol. 2015 Jan;95(1):143-56. doi: 10.1111/mmi.12853. Epub 2014 Nov 25.

31.

TrypanoCyc: a community-led biochemical pathways database for Trypanosoma brucei.

Shameer S, Logan-Klumpler FJ, Vinson F, Cottret L, Merlet B, Achcar F, Boshart M, Berriman M, Breitling R, Bringaud F, Bütikofer P, Cattanach AM, Bannerman-Chukualim B, Creek DJ, Crouch K, de Koning HP, Denise H, Ebikeme C, Fairlamb AH, Ferguson MA, Ginger ML, Hertz-Fowler C, Kerkhoven EJ, Mäser P, Michels PA, Nayak A, Nes DW, Nolan DP, Olsen C, Silva-Franco F, Smith TK, Taylor MC, Tielens AG, Urbaniak MD, van Hellemond JJ, Vincent IM, Wilkinson SR, Wyllie S, Opperdoes FR, Barrett MP, Jourdan F.

Nucleic Acids Res. 2015 Jan;43(Database issue):D637-44. doi: 10.1093/nar/gku944. Epub 2014 Oct 9.

32.

Oxacillin-susceptible methicillin-resistant Staphylococcus aureus (OS-MRSA), a hidden resistant mechanism among clinically significant isolates in the Wessex region/UK.

Saeed K, Ahmad N, Dryden M, Cortes N, Marsh P, Sitjar A, Wyllie S, Bourne S, Hemming J, Jeppesen C, Green S.

Infection. 2014 Oct;42(5):843-7. doi: 10.1007/s15010-014-0641-1. Epub 2014 Jun 12. Erratum in: Infection. 2014 Oct;42(5):949.

PMID:
24919530
33.

Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects.

Patterson S, Wyllie S.

Trends Parasitol. 2014 Jun;30(6):289-98. doi: 10.1016/j.pt.2014.04.003. Epub 2014 Apr 26. Review.

34.

Norspermidine is not a self-produced trigger for biofilm disassembly.

Hobley L, Kim SH, Maezato Y, Wyllie S, Fairlamb AH, Stanley-Wall NR, Michael AJ.

Cell. 2014 Feb 13;156(4):844-54. doi: 10.1016/j.cell.2014.01.012.

35.

Biochemical and genetic characterization of Trypanosoma cruzi N-myristoyltransferase.

Roberts AJ, Torrie LS, Wyllie S, Fairlamb AH.

Biochem J. 2014 Apr 15;459(2):323-32. doi: 10.1042/BJ20131033.

36.

Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis.

Perry MR, Wyllie S, Raab A, Feldmann J, Fairlamb AH.

Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19932-7. doi: 10.1073/pnas.1311535110. Epub 2013 Oct 28.

37.

Trypanosoma brucei (UMP synthase null mutants) are avirulent in mice, but recover virulence upon prolonged culture in vitro while retaining pyrimidine auxotrophy.

Ong HB, Sienkiewicz N, Wyllie S, Patterson S, Fairlamb AH.

Mol Microbiol. 2013 Oct;90(2):443-55. doi: 10.1111/mmi.12376. Epub 2013 Sep 9.

38.

The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.

Patterson S, Wyllie S, Stojanovski L, Perry MR, Simeons FR, Norval S, Osuna-Cabello M, De Rycker M, Read KD, Fairlamb AH.

Antimicrob Agents Chemother. 2013 Oct;57(10):4699-706. doi: 10.1128/AAC.00722-13. Epub 2013 Jul 15.

39.

Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.

De Rycker M, Hallyburton I, Thomas J, Campbell L, Wyllie S, Joshi D, Cameron S, Gilbert IH, Wyatt PG, Frearson JA, Fairlamb AH, Gray DW.

Antimicrob Agents Chemother. 2013 Jul;57(7):2913-22. doi: 10.1128/AAC.02398-12. Epub 2013 Apr 9. Erratum in: Antimicrob Agents Chemother. 2014 Dec;58(12):7622.

40.

Hantavirus and pet rodents.

Featherstone CA, Wyllie S, Frost AJ, McElhinney L, Fooks AR.

Vet Rec. 2013 Apr 6;172(14):370. doi: 10.1136/vr.f2085. No abstract available.

PMID:
23564859
41.

Allosteric activation of trypanosomatid deoxyhypusine synthase by a catalytically dead paralog.

Nguyen S, Jones DC, Wyllie S, Fairlamb AH, Phillips MA.

J Biol Chem. 2013 May 24;288(21):15256-67. doi: 10.1074/jbc.M113.461137. Epub 2013 Mar 21.

42.

Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.

Thwaites G, Auckland C, Barlow G, Cunningham R, Davies G, Edgeworth J, Greig J, Hopkins S, Jeyaratnam D, Jenkins N, Llewelyn M, Meisner S, Nsutebu E, Planche T, Read RC, Scarborough M, Soares M, Tilley R, Török ME, Williams J, Wilson P, Wyllie S, Walker AS; United Kingdom Clinical Infection Research Group.

Trials. 2012 Dec 18;13:241. doi: 10.1186/1745-6215-13-241.

43.

Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation.

Wyllie S, Patterson S, Fairlamb AH.

Antimicrob Agents Chemother. 2013 Feb;57(2):901-6. doi: 10.1128/AAC.01788-12. Epub 2012 Dec 3.

44.

Chemical, genetic and structural assessment of pyridoxal kinase as a drug target in the African trypanosome.

Jones DC, Alphey MS, Wyllie S, Fairlamb AH.

Mol Microbiol. 2012 Oct;86(1):51-64. doi: 10.1111/j.1365-2958.2012.08189.x. Epub 2012 Aug 16.

45.

The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.

Wyllie S, Patterson S, Stojanovski L, Simeons FR, Norval S, Kime R, Read KD, Fairlamb AH.

Sci Transl Med. 2012 Feb 1;4(119):119re1. doi: 10.1126/scitranslmed.3003326.

46.

Quinol derivatives as potential trypanocidal agents.

Capes A, Patterson S, Wyllie S, Hallyburton I, Collie IT, McCarroll AJ, Stevens MF, Frearson JA, Wyatt PG, Fairlamb AH, Gilbert IH.

Bioorg Med Chem. 2012 Feb 15;20(4):1607-15. doi: 10.1016/j.bmc.2011.12.018. Epub 2011 Dec 27.

47.

Comparative proteomics profiling of a gentamicin-attenuated Leishmania infantum cell line identifies key changes in parasite thiol-redox metabolism.

Daneshvar H, Wyllie S, Phillips S, Hagan P, Burchmore R.

J Proteomics. 2012 Feb 16;75(5):1463-71. doi: 10.1016/j.jprot.2011.11.018. Epub 2011 Nov 28.

PMID:
22154982
48.

Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent?

Perry MR, Wyllie S, Prajapati VK, Feldmann J, Sundar S, Boelaert M, Fairlamb AH.

PLoS Negl Trop Dis. 2011 Sep;5(9):e1227. doi: 10.1371/journal.pntd.0001227. Epub 2011 Sep 27. No abstract available.

49.

Methylglyoxal metabolism in trypanosomes and leishmania.

Wyllie S, Fairlamb AH.

Semin Cell Dev Biol. 2011 May;22(3):271-7. doi: 10.1016/j.semcdb.2011.02.001. Epub 2011 Feb 15. Review.

50.

Dissecting the metabolic roles of pteridine reductase 1 in Trypanosoma brucei and Leishmania major.

Ong HB, Sienkiewicz N, Wyllie S, Fairlamb AH.

J Biol Chem. 2011 Mar 25;286(12):10429-38. doi: 10.1074/jbc.M110.209593. Epub 2011 Jan 14.

Supplemental Content

Loading ...
Support Center